HDAC6 Inhibition Restores Docetaxel Sensitivity in Resistant Prostate Cancer Cells
A new preclinical study published in Frontiers in Pharmacology, suggests that inhibiting the enzyme HDAC6 could help overcome resistance to docetaxel, a chemotherapy drug widely used in advanced prostate cancer. The findings identify a potential strategy for restoring chemotherapy sensitivity in castration-resistant prostate cancer (CRPC).
HDAC6 is an enzyme involved in regulating microtubules, the cellular structures targeted by docetaxel. Researchers investigated whether blocking HDAC6 could make resistant cancer cells vulnerable to chemotherapy again. They used two prostate cancer cell lines, DU145 and 22Rv1, that had been experimentally adapted to withstand increasing concentrations of docetaxel.
The researchers tested several experimental HDAC inhibitors and identified a compound called 9b, which selectively inhibited HDAC6. Treatment increased tubulin acetylation, disrupted cell division, and reduced cancer cell migration. Most importantly, combining 9b with docetaxel produced synergistic cancer cell killing, including increased apoptosis, in cells that had previously developed resistance to chemotherapy.
Further experiments revealed that HDAC6 inhibition suppressed MYC, a major regulator of cancer cell growth and survival. Reducing MYC expression independently also increased docetaxel sensitivity. Moreover, genetically disabling HDAC6 produced similar effects, strengthening the evidence that HDAC6 contributes to chemotherapy resistance rather than merely being associated with it.
These findings suggest that HDAC6 inhibitors could eventually be combined with docetaxel to improve treatment effectiveness in resistant prostate cancer. However, all functional experiments were performed in laboratory cell lines, not in patients or animal tumor models. Compound 9b remains experimental, and its safety, appropriate dosing, and effectiveness in humans are unknown. Further studies using patient-derived tumor models and animal experiments will be needed before clinical trials can establish whether HDAC6 inhibition offers a meaningful therapeutic benefit.
Source.

Leave a Reply
Want to join the discussion?Feel free to contribute!